Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Change in Energy Pathway Enables Malignant Melanoma Cells to Survive BRAF Inhibition

By BiotechDaily International staff writers
Posted on 18 Mar 2013
A recent paper showed that BRAF (v-raf murine sarcoma viral oncogene homolog B1) -positive metastatic malignant melanoma cells survive treatment with BRAF inhibitors by increasing dependence on mitochondrial activity with concomitant change of energy production to the oxidative phosphorylation pathway.

The protein encoded by the BRAF gene plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene have been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small-cell lung carcinoma, and lung adenocarcinoma. Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis.

Investigators at Harvard University Medical School (Boston, MA, USA) reported in the March 7, 2013, online edition of the journal Cancer Cell that BRAF inhibition induced an oxidative phosphorylation gene program, mitochondrial biogenesis, and the increased expression of the mitochondrial master regulator, PGC1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1alpha is a transcriptional coactivator that regulates the genes involved in energy metabolism and provides a direct link between external physiological stimuli and the regulation of mitochondrial biogenesis.

The investigators showed that a target of BRAF, the melanocyte lineage factor MITF, directly regulated the expression of PGC1alpha. Melanomas with activation of the BRAF/MAPK pathway had suppressed levels of MITF and PGC1alpha and decreased oxidative metabolism. Conversely, treatment of BRAF-mutated melanomas with BRAF inhibitors rendered them addicted to oxidative phosphorylation.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," said Dr. David E. Fisher, professor of dermatology at Harvard University Medical School. "While current BRAF inhibitor treatment is a major improvement – shrinking tumors in most patients and extending survival for several months – patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

"These findings suggest that combination treatment with mitochondrial inhibitors could improve the efficacy of BRAF inhibitors in malignant melanoma," said Dr. Fisher. "Several small molecules that target mitochondrial metabolism have been identified by investigators here at Harvard and elsewhere, and laboratory investigations of specific combinations of BRAF inhibitors with mitochondrial antagonists are currently underway."

Related Links:

Harvard University Medical School



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.